Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2019 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated in dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement...
October 10, 2019 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
September 25, 2019 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Management to discuss the results on a call scheduled for today, September 25, 2019 at...
August 13, 2019 07:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
July 17, 2019 16:44 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Proposed Public Offering of Common Stock

BROOKLYN, N.Y., July 17, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an...
July 08, 2019 16:03 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies...
July 08, 2019 16:01 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency (EPI).Patients in...
June 07, 2019 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers

BROOKLYN, N.Y., June 07, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), today announced that both the United States Patent and Trademark Office and the...
May 23, 2019 08:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial

Enrollment in AzurRx’s Phase II OPTION study has reached target of 30-35 patientsScreening activities have been completed in AzurRx’s Phase II Option studyTop-line data expected in Summer 2019 ...
May 20, 2019 14:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference

Statistical significance achieved on multiple secondary endpointsNew data underscore the potential of MS1819 to provide meaningful clinical benefits to patients suffering from exocrine pancreatic...